Companies
ProQR Therapeutics
the Axiomer platform uses ADAR-recruiting editing oligonucleotides (EONs); AX-0810, a GalNAc-conjugated EON modulating NTCP for cholestatic liver disease, produced the first clinical validation of the platform in 2026 — a dose-dependent up to 8-fold rise in total bile acids at 6 mg/kg (above the 2-fold target-engagemen…
- Country
- Netherlands
- Ticker
- NASDAQ:PRQR
NTCP editor (AX-0810)
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $59.2 million raised in June 2026 through an underwritten registered direct offering and a concurrent private placement with Eli Lilly and Company | proqr.com |
| Headcount | 186 employees on average for 2025 | proqr.com |
| Revenue | €15,906,000 in net revenue for the full year 2025; €10,792,000 in net revenue for the first six months of 2026 | proqr.com |
| Production site | Headquarters and laboratory facilities are located at Zernikedreef 9, Leiden, the Netherlands | sec.gov |
| Regulatory approval | Clinical Trial Application (CTA) for Phase 1 study of AX-0810 authorized in Europe (October 2025) | proqr.gcs-web.com · proqr.com |
Independent sources: sec.gov
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| RNA editing (ADAR) therapeutics | therapeutics-platforms | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.